Hung-wei Wang
Taitung, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Systemic Treatment Strategies for Recurrent Hepatocellular Carcinoma Following Liver Transplantation: A 20-y Retrospective Analysis With Clinical Insights.
Journal: Transplantation
Published: May 01, 2026
Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B.
Journal: Annals of medicine
Published: April 20, 2026
Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
Journal: Annals of transplantation
Published: March 24, 2026
Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.
Journal: Liver cancer
Published: February 06, 2026
Reply to the Letter on "Clinical implications of fibrosis marker dynamics after hepatitis C cure: insights from paired biopsies".
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: January 11, 2026
Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort Study.
Journal: Liver cancer
Published: November 13, 2025
Metabolic and liver stiffness measures for hepatocellular carcinoma risk stratification after viral eradication in chronic hepatitis C.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: September 21, 2025
Clinical implications of fibrosis marker dynamics after hepatitis C cure: Insights from paired biopsies.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: August 28, 2025
Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma.
Journal: Clinical and molecular hepatology
Published: July 03, 2025
Reply to comment on "Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program".
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: April 12, 2025
Reply to comment on "Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program".
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: April 12, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: November 11, 2024
Last Updated: 09/26/2026